- |||||||||| Journal, Epigenetic controller: DNA methylation pattern in somatotroph pituitary neuroendocrine tumors. (Pubmed Central) - Jan 15, 2024
DNA methylation profiling confirmed the existence of three molecular subtypes of somatotroph PitNETs. High expression of NR5A1 and GIPR in subtype 1 tumors is correlated with specific methylation of both genes.
- |||||||||| Signifor (pasireotide) / Recordati
Journal: Pasireotide - potential treatment option for McCune Albright-associated acromegaly. (Pubmed Central) - Jan 12, 2024
All three patients developed intermittent impaired fasting glucose, without the need for glucose-lowering drugs. Thus, pasireotide LAR is clearly useful as third-line therapy, and potentially even as second-line therapy, in MAS-associated acromegaly.
- |||||||||| Signifor (pasireotide) / Recordati
Journal: A Novel Somatostatin Receptor Ligand for Human ACTH- and GH-secreting Pituitary Adenomas. (Pubmed Central) - Jan 12, 2024
This first study on a novel somatostatin receptor 5-preferring ligand indicates that HTL0030310 can inhibit hormonal secretion in human ACTH- and GH-secreting pituitary adenomas. These findings suggest a potential new avenue for somatostatin ligands in the treatment of Cushing's disease and acromegaly.
- |||||||||| Journal: Acromegaly and Bone: An Update. (Pubmed Central) - Jan 6, 2024
Due to the high epidemiological and clinical impact of this newly discovered comorbidity of acromegaly, this topic has progressively become more important and prominent over the years, and the pertinent literature has been enriched by new findings on the pathophysiology and treatment. The aim of this narrative review was to discuss these novel findings, integrating them with the seminal observations, in order to give the reader an updated view of how the field of acromegaly and bone is developing, from strong clinical observations to a mechanistic understanding and possible prevention and treatment.
- |||||||||| Somavert (pegvisomant) / Pfizer, Signifor (pasireotide) / Recordati
Biomarker, Review, Journal: Biomarkers of response to treatment in acromegaly. (Pubmed Central) - Jan 3, 2024
Biomarkers for fg-SRL that can already be applied in clinical practice are: gender, age, pretreatment GH and IGF-I levels, cytokeratin granulation pattern, and the expression of somatostatin receptor type 2. Using biomarkers of response could guide treatment towards precision medicine with greater efficacy and lower costs.
- |||||||||| Acromegaly and Its Impact on Cognitive Functioning in Patients with Pituitary Adenoma (Shubert Complex (Posters 1-60) / Majestic Complex (Posters 61-120)) - Dec 26, 2023 - Abstract #INSNewYork2024INS_Newyork_1239;
Neuropsychological examination should therefore be the gold standard in the diagnosis of this group of patients. This would allow for the implementation of an appropriate therapeutic strategy and increase the chance of improving the quality of life of people treated for acromegaly.
- |||||||||| Journal: Live Fast, Die Young? (Pubmed Central) - Dec 25, 2023
Lower ANGPTL-8 in patients with acromegaly and NAFLD implies this hormone may be raised because of insulin resistance rather than being a cause for NAFLD. No abstract available
- |||||||||| Journal: Pathologic Characteristics of Somatotroph Pituitary Tumors-An Observational Single-Center Study. (Pubmed Central) - Dec 23, 2023
Patients with a higher Ki-67 index were younger (p < 0.001) and more often diagnosed with genetic syndromes (p = 0.02); they had higher GH concentrations (p = 0.007), larger tumors (p = 0.006), and cavernous sinus invasions more frequently (p = 0.022). The pathologic characteristics of somatotroph pituitary tumors are associated with patient's age, sex, hormonal results, tumor size, and the degree of extrasellar expansion.
- |||||||||| Biomarker, Journal: Serum Phosphorus and Calcium as Biomarkers of Disease Status in Acromegaly. (Pubmed Central) - Dec 23, 2023
Based on logistic regression, the higher the serum phosphorus level, the lower the odds of achieving remission (an increase in one unit leads to a decrease in the chance of about 80%). In conclusion, phosphorus and calcium can be effective biochemical markers for predicting disease status in acromegaly.
- |||||||||| Review, Journal: Ectopic Hormonal Syndromes: Cushing's Syndrome and Acromegaly. (Pubmed Central) - Dec 19, 2023
The frequency of neuroendocrine neoplasms and other neoplasms with neuroendocrine differentiation has been increasing in recent decades. The review of the available data on these tumors, their classification, and improvements in diagnostic and therapeutic procedures is important to understand the relevance of ectopic Cushing's syndrome and acromegaly in clinical practice.
- |||||||||| Review, Journal: Acromegaly and Cancer: An Update. (Pubmed Central) - Dec 19, 2023
Rigorous surveillance of endocrine diseases may contribute to increased tumor detection. Personalized screening should probably be recommended.
- |||||||||| Retrospective data, Review, Journal: Impulse Control Disorders in Patients with Pituitary Tumors Treated with Dopamine Agonists: A Systematic Review. (Pubmed Central) - Dec 19, 2023
Given ICDs were reported to be highly prevalent in some studies, clinicians should be mindful of these potentially serious disorders. ICD screening tools validated for use in patients with pituitary tumors combined with prospective studies including appropriate controls, are necessary to accurately establish prevalence of ICDs and true impact of DAs in their development.
- |||||||||| Journal: Genomics, Transcriptomics, and Epigenetics of Sporadic Pituitary Tumors. (Pubmed Central) - Dec 19, 2023
In recent years, important advances in the understanding of the molecular pathogenesis of PT have been made, including the genomic, transcriptomic, epigenetic, and proteomic characterization of these neoplasms. In this review, we summarize the available molecular information pertaining the oncogenesis of PT.
- |||||||||| Journal: Radiotherapy and Mortality in Pituitary Adenomas. (Pubmed Central) - Dec 19, 2023
Modern techniques mitigate complications, and although safer, long-term studies are needed. Multidisciplinary evaluation guides the treatment decision, optimizing efficacy and minimizing risk, ultimately improving the patient's quality of life.
- |||||||||| Somavert (pegvisomant) / Pfizer
Journal: Efficacy and Safety of Pegvisomant in the Treatment of Acromegaly. (Pubmed Central) - Dec 19, 2023
Furthermore, different combinations of pegvisomant and other therapeutic agents aiming at reduction of acromegaly disease activity have been proposed to increase or retain effectiveness while lowering side effects and cost. This review aims to assess current clinical data on the safety and efficacy of pegvisomant while also addressing controversies surrounding its use.
- |||||||||| Review, Journal: Differences between bone health parameters in adults with acromegaly and growth hormone deficiency: A systematic review. (Pubmed Central) - Dec 11, 2023
This review summarizes available data on the effects of acromegaly and GHD on parameters of bone health such as aBMD, volumetric bone mineral density (vBMD) and microarchitecture assessed by HRpQCT and other techniques, trabecular bone score (TBS) and fracture assessment. More research is needed to identify reliable predictors of fracture risk and to determine how best to screen for and treat those patients at risk so that bone health is optimized in these patients.
- |||||||||| Journal: Predictors of postoperative remission of acromegaly. (Experience of the Burdenko Neurosurgical Center). (Pubmed Central) - Dec 10, 2023
Significant predictors of acromegaly remission after neurosurgical treatment were age, preoperative level of growth hormone, tumor size and location, growth hormone and IGF-1 index in early postoperative period and residual tumor after surgery. Multivariate analysis revealed a significant association of acromegaly remission with small tumor size, low postoperative level of growth hormone and no residual tumor within 3-6 month after surgery.
- |||||||||| Review, Journal: Hotspots of Somatic Genetic Variation in Pituitary Neuroendocrine Tumors. (Pubmed Central) - Dec 9, 2023
Since the associations of BRAF, USP48, and SF3B1 hotspot variants with PitNETs are very recent, their effects on clinical phenotypes are still unknown. Further research is required to fully define the role of these genetic defects as disease biomarkers and therapeutic targets.
- |||||||||| Enrollment closed, Trial primary completion date: ACRODAT Prospective Evaluation Study (clinicaltrials.gov) - Dec 4, 2023
P=N/A, N=500, Active, not recruiting,
Risk factors for cancer need to be further explored to monitor patients with acromegaly at a high risk for cancer more carefully. Recruiting --> Active, not recruiting | Trial primary completion date: May 2023 --> Oct 2023
- |||||||||| Review, Journal: Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly. (Pubmed Central) - Dec 3, 2023
Measurement of both GH and IGF-I remains an essential component of diagnosis and monitoring the effectiveness of treatment in acromegaly; however, treatment goals based only on previously identified absolute thresholds are not appropriate without taking into account the assay and reference ranges being employed. Treatment goals should be individualized considering biochemical improvement from an untreated baseline, symptoms of disease, risks, burdens and costs of complex treatment regimens, comorbidities, and quality of life.
- |||||||||| Tepezza (teprotumumab) / Roche, Amgen
Journal: The effect of acromegaly on thyroid disease. (Pubmed Central) - Dec 1, 2023
Recent studies have reported that the IGF-1 receptor (IGF-1R) plays an important role in the pathogenesis of TAO, and the IGF-1R inhibitor teprotumumab involves significantly improved disease endpoints in patients with active TAO. Thyroid-stimulating hormone (TSH) receptor (TSHR) and IGF-1R co-immunoprecipitate in orbital and thyroid tissues to form a functional complex; thus, combined therapy targeting TSHR and IGF-1R may be more effective than single therapy.
- |||||||||| Trial completion, Trial completion date: Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor (clinicaltrials.gov) - Nov 29, 2023
P=N/A, N=25, Completed,
A sex-related difference can be considered in the evolution and prognosis of these tumors, but further studies are needed to confirm this hypothesis. Active, not recruiting --> Completed | Trial completion date: Jul 2023 --> Nov 2023
- |||||||||| octreotide 3-month extended release (Debio 4126) / Debiopharm
Enrollment closed, Phase classification, Trial completion date, Trial primary completion date: OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Nov 29, 2023
P1, N=30, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Jul 2023 --> Nov 2023 Recruiting --> Active, not recruiting | Phase classification: P1b --> P1 | Trial completion date: Jun 2025 --> Dec 2024 | Trial primary completion date: May 2025 --> Nov 2024
- |||||||||| Journal: Acromegaly versus hypogonadism: bone fragility and evaluation. (Pubmed Central) - Nov 27, 2023
Patients with acromegaly, regardless of gonadal status, have significantly higher BMD but lower TBS than hypogonadal patients. Moreover, disease activity and hypogonadism do not influence BMD, TBS or VF in acromegaly.
- |||||||||| Journal: Pituitary tumor registry: a multidisciplinary program protocol. (Pubmed Central) - Nov 17, 2023
For a long time, patients with pituitary adenomas should be observed. Implementing a registration system would greatly reduce the challenges of patients' follow-up so that their monitoring can be improved.
|
